Gene editing used to treat muscular dystrophy in mice
CRISPR/Cas9 system injected into muscle or bloodstream restored function of dystrophin gene, marking an important step in gene therapy research.
Source: Ramon Andrade 3DCiencia / Science Photo Library
Duchenne muscular dystrophy is caused by mutations in the dystrophin gene, which results in muscle degeneration. Gene therapy has been proposed as a possible treatment, but the large size of the gene is a major challenge.
Now, researchers from Duke University, North Carolina, have successfully restored function of the mutated dystrophin gene in mice by packaging the CRISPR/Cas9 gene editing system into a virus and injecting it into the muscle or bloodstream.
This resulted in some expression of functional dystrophin protein in cardiac and skeletal muscle, alongside improvements in muscle biochemistry and force.
The research, published in Science (online, 31 December 2015), represents the first time that the CRISPR/Cas9 system has been used to treat a genetic disease in an adult mammal with a delivery method that could be extended to human clinical trials.
Citation: Clinical Pharmacist DOI: 10.1211/PJ.2016.20200390
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com